In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
General Oncology
FEATURED CONTENT
-
-
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective. -
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money. -
A Novel Method for Biomarker Discovery in Clinical Trials
A new study reveals a unique method of biomarker discovery that has the potential to be used to identify responder subpopulations in clinical trials. -
Study Reports Marijuana Use Among Patients With Cancer May Be Increasing While Opioid Use Stays Stable, but Questions Remain
The proportion of participants with cancer who used marijuana increased 118% from the period of 2005 to 2014.
GENERAL ONCOLOGY CANCERS NEWS
NCI Pediatric MATCH Study Shows High Rate of Targetable Molecular Alterations in Tumor Specimens
Private Insurers Pay 241 Percent of What Medicare Would Pay
Cannabis Legalization Not Tied to Higher Health Care Utilization
FDA Panel Backs Pexidartinib for Rare Tumor, Votes Against Quizartinib for FLT3-ITD AML
Risk for Cancer Increased in Men, Women With T2DM
Want to read more?
Please login or register first to view this content.
Next post in General Oncology
